|
1
|
Tokunaga E, Oki E, Egashira A, Sadanaga N,
et al: Deregulation of the Akt pathway in human cancer. Curr Cancer
Drug Targets. 8:27–36. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stiles B, Gilman V, Khanzenzon N, et al:
Essential role of AKT-1/protein kinase B alpha in PTEN-controlled
tumorigenesis. Mol Cell Biol. 22:3842–3851. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bellacosa A, Testa JR, Moore R and Larue
L: A portrait of AKT kinases: human cancer and animal models depict
a family with strong individualities. Cancer Biol Ther. 3:268–275.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Manning BD and Cantley LC: AKT/PKB
signaling: navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sukawa Y, Yamamoto H, Nosho K, et al:
Alterations in the human epidermal growth factor receptor
2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
World J Gastroenterol. 18:6577–6586. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Berg M and Soreide K: EGFR and downstream
genetic alterations in KRAS/BRAF and PI3K/AKT pathways in
colorectal cancer: implications for targeted therapy. Discov Med.
14:207–214. 2012.PubMed/NCBI
|
|
9
|
Ng L, Poon RT and Pang R: Biomarkers for
predicting future metastasis of human gastrointestinal tumors. Cell
Mol Life Sci. 70:3631–3656. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cheung M and Testa JR: Diverse mechanisms
of AKT pathway activation in human malignancy. Curr Cancer Drug
Targets. 13:234–244. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Downward J: PI 3-kinase, Akt and cell
survival. Semin Cell Dev Biol. 15:177–182. 2004. View Article : Google Scholar
|
|
12
|
Radisavljevic Z: AKT as locus of cancer
angiogenic robustness and fragility. J Cell Physiol. 228:21–24.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu M and Mo YY: The Akt-associated
microRNAs. Cell Mol Life Sci. 69:3601–3612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Park BK, Zeng X and Glazer RI: Akt1
induces extracellular matrix invasion and matrix
metalloproteinase-2 activity in mouse mammary epithelial cells.
Cancer Res. 61:7647–7653. 2001.PubMed/NCBI
|
|
15
|
Kim D, Kim S, Koh H, et al: Akt/PKB
promotes cancer cell invasion via increased motility and
metalloproteinase production. FASEB J. 15:1953–1962. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tanno S, Tanno S, Mitsuuchi Y, Altomare
DA, Xiao GH and Testa JR: AKT activation up-regulates insulin-like
growth factor I receptor expression and promotes invasiveness of
human pancreatic cancer cells. Cancer Res. 61:589–593. 2001.
|
|
17
|
Grille SJ, Bellacosa A, Upson J, et al:
The protein kinase Akt induces epithelial mesenchymal transition
and promotes enhanced motility and invasiveness of squamous cell
carcinoma lines. Cancer Res. 63:2172–2178. 2003.PubMed/NCBI
|
|
18
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Granville CA, Memmott RM, Gills JJ and
Dennis PA: Handicapping the race to develop inhibitors of the
phosphoinositide 3-kinase/Akt/mammalian target of rapamycin
pathway. Clin Cancer Res. 12:679–689. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cully M, You H, Levine AJ and Mak TW:
Beyond PTEN mutations: the PI3K pathway as an integrator of
multiple inputs during tumorigenesis. Nat Rev Cancer. 6:184–192.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Markman B, Atzori F, Pérez-García J,
Tabernero J and Baselga J: Status of PI3K inhibition and biomarker
development in cancer therapeutics. Ann Oncol. 21:683–691. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yuan R, Kay A, Berg WJ and Lebwohl D:
Targeting tumorigenesis: development and use of mTOR inhibitors in
cancer therapy. J Hematol Oncol. 2:452009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li H, Zhao L, Yang Z, Funder JW and Liu
JP: Telomerase is controlled by protein kinase Calpha in human
breast cancer cells. J Biol Chem. 273:33436–33442. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kang SS, Kwon T, Kwon DY and Do SI: Akt
protein kinase enhances human telomerase activity through
phosphorylation of telomerase reverse transcriptase subunit. J Biol
Chem. 274:13085–13090. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim JH, Park SM, Kang MR, et al: Ubiquitin
ligase MKRN1 modulates telomere length homeostasis through a
proteolysis of hTERT. Genes Dev. 19:776–781. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Karamitopoulou E: Tumor budding cells,
cancer stem cells and epithelial-mesenchymal transition-type cells
in pancreatic cancer. Front Oncol. 2:2092013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu Z, Li Q, Li K, et al: Telomerase
reverse transcriptase promotes epithelial-mesenchymal transition
and stem cell-like traits in cancer cells. Oncogene. 32:4203–4213.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fidler IJ: The pathogenesis of cancer
metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev
Cancer. 3:453–458. 2003.
|
|
29
|
Claesson-Welsh L and Welsh M: VEGFA and
tumour angiogenesis. J Intern Med. 273:114–127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Karar J and Maity A: PI3K/AKT/mTOR pathway
in angiogenesis. Front Mol Neurosci. 4:512011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sasaki T, Kuniyasu H, Luo Y, et al: AKT
activation and telomerase reverse transcriptase expression are
concurrently associated with prognosis of gastric cancer.
Pathobiology. 81:36–41. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sasaki T, Kuniyasu H, Luo Y, et al:
Increased phosphorylation of AKT in high-risk gastric mucosa.
Anticancer Res. 33:3295–3300. 2013.PubMed/NCBI
|
